TY - JOUR
T1 - Short Communication
T2 - Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy
AU - Haslett, Kate
AU - De Ruysscher, Dirk
AU - Dziadziuszko, Rafal
AU - Guckenberger, Matthias
AU - Pechoux, Cecile Le
AU - Nestle, Ursula
AU - Slotman, Ben
AU - Faivre-Finn, Corinne
N1 - Funding Information:
The CREST trial was funded by the Dutch Cancer Society (CKTO), Dutch Lung Cancer Research Group, Cancer Research UK, Manchester Academic Health Science Centre Trials Coordination Unit, and the UK National Cancer Research Network.
Funding Information:
The CREST trial was funded by the Dutch Cancer Society (CKTO) , Dutch Lung Cancer Research Group , Cancer Research UK , Manchester Academic Health Science Centre Trials Coordination Unit , and the UK National Cancer Research Network .
Publisher Copyright:
© 2018
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objectives: The results of the randomized phase 3 CREST trial evaluating the use of thoracic radiotherapy for extensive-stage small-cell lung cancer (ES-SCLC) were published in the Lancet in 2015. The primary endpoint (10% overall survival difference at 1-year) was not achieved, but there was significant improvement in 2-year overall survival (13% vs 3%; p = 0.004) and low toxicity rates, suggesting thoracic radiotherapy should be considered for ES-SCLC patients who respond to chemotherapy. Questions have been raised as to whether these results will lead to a change in practice. Materials and methods: We developed an electronic survey to determine the impact of the publication on clinical practice across some European countries. Results and conclusion: We report the results of our survey, which suggest the CREST trial has changed practice, resulting in an increase in the use of thoracic radiotherapy amongst the surveyed centers from 25% to 85%. Furthermore the dose and fractionation schedule used in the trial has been widely adopted across Europe.
AB - Objectives: The results of the randomized phase 3 CREST trial evaluating the use of thoracic radiotherapy for extensive-stage small-cell lung cancer (ES-SCLC) were published in the Lancet in 2015. The primary endpoint (10% overall survival difference at 1-year) was not achieved, but there was significant improvement in 2-year overall survival (13% vs 3%; p = 0.004) and low toxicity rates, suggesting thoracic radiotherapy should be considered for ES-SCLC patients who respond to chemotherapy. Questions have been raised as to whether these results will lead to a change in practice. Materials and methods: We developed an electronic survey to determine the impact of the publication on clinical practice across some European countries. Results and conclusion: We report the results of our survey, which suggest the CREST trial has changed practice, resulting in an increase in the use of thoracic radiotherapy amongst the surveyed centers from 25% to 85%. Furthermore the dose and fractionation schedule used in the trial has been widely adopted across Europe.
KW - European practice
KW - Extensive stage small-cell lung cancer
KW - Radiotherapy
KW - Survey
U2 - 10.1016/j.ctarc.2018.08.004
DO - 10.1016/j.ctarc.2018.08.004
M3 - Article
SN - 2468-2942
VL - 17
SP - 18
EP - 22
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
ER -